Komori
General Meetings of Shareholders4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Executive Compensation Overview

From fiscal 2026, the bonus (STI) will be based solely on company-wide KPIs, with R&D milestones and strategic objectives added. For the long-term incentive (PSU), the R&D KPI will be removed and relative TSR established as an independent KPI, with the 3 metrics weighted equally.

Worth reading
—
Scored from 0 of 4 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Director nomineeNumber of candidates: Not disclosed; of whom new and outside candidates: Not disclosed
Resolutions for the General Meeting of Shareholders
ItemDetails
Director nomineeNumber of candidates: Not disclosed; of whom new and outside candidates: Not disclosed
Items this document does not state (5)
Type of shareholders' meetingDate and timeMatters for resolutionShareholder ProposalPercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To simplify the compensation system, align the entire management team under the “One Takeda” approach, and strengthen the link to the fulfillment of individual responsibilities. In addition, to evaluate R&D results over shorter cycles and strengthen the link to shareholder interests by reflecting TSR directly and transparently in payouts.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Executive Compensation Overview | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori